Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Enterprise Value (2016 - 2025)

Ptc Therapeutics has reported Enterprise Value over the past 14 years, most recently at -$1.9 billion for Q4 2025.

  • Quarterly results put Enterprise Value at -$1.9 billion for Q4 2025, down 70.69% from a year ago — trailing twelve months through Dec 2025 was -$1.9 billion (down 70.69% YoY), and the annual figure for FY2025 was -$1.9 billion, down 70.69%.
  • Enterprise Value for Q4 2025 was -$1.9 billion at Ptc Therapeutics, down from -$1.7 billion in the prior quarter.
  • Over the last five years, Enterprise Value for PTCT hit a ceiling of -$286.3 million in Q1 2023 and a floor of -$2.0 billion in Q1 2025.
  • Median Enterprise Value over the past 5 years was -$880.8 million (2023), compared with a mean of -$947.3 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 66.77% in 2022 and later crashed 243.73% in 2024.
  • Ptc Therapeutics' Enterprise Value stood at -$773.4 million in 2021, then surged by 46.89% to -$410.7 million in 2022, then tumbled by 113.47% to -$876.7 million in 2023, then decreased by 29.99% to -$1.1 billion in 2024, then plummeted by 70.69% to -$1.9 billion in 2025.
  • The last three reported values for Enterprise Value were -$1.9 billion (Q4 2025), -$1.7 billion (Q3 2025), and -$2.0 billion (Q2 2025) per Business Quant data.